Ajinomoto Bio-Pharma Services Awarded Three 'CDMO Leadership Awards'

Ajinomoto Bio-Pharma Services

PR99764

 

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 14, 2023 /PRNewswire=KYODO JBN/ --

 

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of

biopharmaceutical contract development and manufacturing services, received

three CDMO Leadership Awards in the categories Capabilities, Compatibility, and

Expertise in both the Overall and Big Pharma respondent groups.

 

Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg

 

Established in 2011, the CDMO Leadership Awards recognize top outsourcing

partners. The awards, rebranded from the CMO Leadership Awards, are presented

by Life Science Leader magazine and Industry Standard Research. 72 contract

manufacturers were assessed by 23 performance metrics in ISR's annual Contract

Manufacturing Quality Benchmarking survey. Respondents only evaluate companies

with which they have worked on an outsourced project within the past 18 months.

Based on ratings of these recent outsourced projects provided by sponsors, this

experiential feedback is analyzed by sponsor company size to reveal leading

CDMOs in different performance categories.

 

"For over a decade, these awards have been the most meaningful for biopharma

organizations striving to obtain optimal outcomes from their outsourcing

activities. Our research arm, ISR Reports, which only surveys drug sponsors who

have worked directly and recently with specific CDMOs, ensures the validity of

these results. Our winners are your gold-medalists of outsourcing." Louis

Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.

 

"We are proud to be recognized by our partners as we continue to invest in new

technologies, quality systems, and facilities to increase our capabilities and

expertise to meet the needs of our clients. We take pride in knowing our

efforts are helping countless patients for years to come." Said Yasuyuki Otake,

General Manager, Bio-Pharma Services Department.

 

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and

manufacturing organization with sites in Belgium, United States, Japan, and

India, providing comprehensive development, cGMP manufacturing, and aseptic

fill finish services for small and large molecule APIs and intermediates.

Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and

capabilities for pre-clinical and pilot programs to commercial quantities,

including Corynex(R) protein expression technology, oligonucleotide synthesis,

antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,

continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is

dedicated to providing a high level of quality and service to meet our client's

needs. Learn more: www.AjiBio-Pharma.com

 

SOURCE: Ajinomoto Bio-Pharma Services

 

CONTACT: info@us.ajibio-pharma.com

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中